Study of Digitoxin with Chemotherapy for Patients with Inoperable Pancreatic Cancer

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called Digitoxin in combination with chemotherapy for patients with pancreatic cancer that cannot be removed by surgery. The main goal of the study is to improve the survival of these patients. Pancreatic cancer is a serious disease where cancer cells form in the tissues of the pancreas, an organ that helps with digestion and blood sugar regulation.

Participants in the study will take Digitoxin tablets by mouth. The study will last for up to one year, during which time the participants’ health and response to the treatment will be closely monitored. The study will look at how long patients live without the cancer getting worse, as well as their overall survival. Researchers will also assess the safety of the treatment and any side effects that may occur.

Throughout the study, various health assessments will be conducted, including checking blood markers that can indicate the presence of cancer. The quality of life of participants will also be evaluated using specific questionnaires. Additionally, the study will involve analyzing certain proteins in the blood that are important for cancer and inflammation. This research aims to provide valuable insights into the potential benefits of using Digitoxin alongside chemotherapy for treating pancreatic cancer.

1 enrollment

Upon joining the study, you will be required to provide written consent to participate. This confirms your understanding and agreement to be part of the trial.

You will undergo a series of initial assessments to confirm eligibility, including a review of your medical history and a physical examination.

2 initial testing

A pregnancy test will be conducted for female patients of childbearing potential within 72 hours before starting treatment. This ensures safety and eligibility for the trial.

Baseline measurements of serum tumor markers, such as CA19-9, CEA, and CA125, will be taken. These markers help in monitoring the disease.

3 start of treatment

You will begin taking digitoxin tablets orally. The dosage is 0.07 mg per tablet. The frequency and duration of administration will be specified by the study team.

The primary goal of this treatment is to improve survival in patients with inoperable pancreatic cancer.

4 ongoing assessments

Every three months, your serum tumor markers will be evaluated to monitor the biochemical response to the treatment.

Radiographic assessments will be conducted to evaluate disease progression. This involves imaging tests to check the size and spread of the cancer.

5 quality of life evaluations

Your quality of life will be assessed using specific questionnaires, EORTC QLQ-C30 and EORTC QLQ-PAN-26, designed to understand the impact of the treatment on your daily life.

6 safety monitoring

Throughout the trial, any side effects or adverse events will be closely monitored to ensure the safety and tolerability of the treatment.

Regular laboratory tests will be conducted to check for any changes in your health status.

7 translational studies

Cytokines, which are proteins important for cancer and inflammation, will be analyzed before starting digitoxin and at three months of treatment. This helps in understanding the biological effects of the treatment.

8 completion of trial

The trial is expected to continue until October 2027. Your participation will contribute to understanding the effectiveness and safety of digitoxin in combination with chemotherapy for pancreatic cancer.

Who Can Join the Study?

Must be a male or female who is 18 years or older.
Male patients with a female partner who can have children must agree to use a reliable method of birth control, such as a condom, during the study and for 6 months after the last dose of the study medication. Choosing not to have sex is acceptable if it is the usual lifestyle choice.
Must have a WHO performance status of 0-2, which means the patient is fully active or able to carry out light work.
Must have a confirmed diagnosis of inoperable adenocarcinoma of the pancreas, which means the cancer cannot be removed by surgery. This must be confirmed by examining tissue from the pancreas or a spread of the cancer.
Must be newly diagnosed and not have started any other treatment for pancreatic cancer.
Must have a disease that can be measured or evaluated by scans, according to specific guidelines (RECIST v1.1).
Must be able to take care of their own medication.
Must have given written consent to participate in the trial.
Female patients who can have children must have a negative pregnancy test within 72 hours before receiving the first treatment. If the urine test is positive or unclear, a blood test will be required.
Female patients who can have children must agree to use a reliable method of birth control during the study and for 6 months after the last dose of the study medication. Choosing not to have sex is acceptable if it is the usual lifestyle choice.

Who Cannot Join the Study?

Patients with any other type of cancer besides pancreatic cancer cannot participate.
Patients who have had surgery to remove their pancreatic cancer are not eligible.
Patients who are under the age of 18 or over the age of 75 cannot participate.
Patients who are pregnant or breastfeeding are not eligible.
Patients who have a serious infection or illness that affects their immune system cannot participate.
Patients who are currently participating in another clinical trial are not eligible.
Patients who have a history of severe allergic reactions to medications used in the trial cannot participate.
Patients who have a mental health condition that affects their ability to understand the trial or follow instructions are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Skaraborg Hospital-Vaestra Goetalandsregionen	Skovde	Sweden

Trial status

Country	Status	Recruitment Start
Sweden	Recruiting	01.12.2024

Trial locations

Investigated drugs:

Digitoxin

Digitoxin is a medication that is being studied for its potential to help treat pancreatic cancer. It is traditionally used to treat heart conditions, but researchers are exploring its ability to work alongside chemotherapy to improve the survival of patients with inoperable pancreatic cancer. In this trial, digitoxin is being combined with chemotherapy to see if it can enhance the effectiveness of the cancer treatment.

Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. It works by stopping or slowing the growth of cancer cells, which grow and divide quickly. In this trial, chemotherapy is being used in combination with digitoxin to see if the two treatments together can improve outcomes for patients with inoperable pancreatic cancer. The goal is to find a more effective treatment approach that can help patients live longer.

Pancreatic adenocarcinoma – Pancreatic adenocarcinoma is a type of cancer that originates in the tissues of the pancreas, an organ located behind the stomach. It typically begins in the ducts that carry digestive enzymes out of the pancreas. As the disease progresses, it can invade nearby organs and spread to other parts of the body. The cancer cells grow uncontrollably, forming a mass or tumor that can interfere with the normal functions of the pancreas. Over time, this can lead to symptoms such as jaundice, weight loss, and abdominal pain. The progression of the disease can vary, but it often advances quickly due to its aggressive nature.

Trial ID:

2024-512128-12-01

Protocol code:

Digi-Panc-1

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Digitoxin with Chemotherapy for Patients with Inoperable Pancreatic Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?